Methylplus™, developed with BioCangen’s USGMAT technology, is the first methylation-based diagnostic tool to meet both performance and cost criteria for practical use in early cancer detection and therapy response prediction.
Competitive Advantages
- Non-invasive: uses plasma or body fluids as the sample source
- Requires only an extremely small amount of DNA (2 ng) for a complete assay
- Compatible with currently existing gene amplification systems
- Mutiplex (2 targets in a single well) and high throughput (96-384 wells)
- Specific: discriminate methylated DNA from background DNA at 1:10,000 ratio
- Sensitive: detection limit as low as 10 pg of input DNA
- Extremely rapid: less than 4 hours from sample preparation to result report.
- Simple: Component-ready kits, streamlined procedure
- Cost-effective: only 15-20% cost of currently used QM real-time PCR/HM real-time PCR
- Reliable: proprietary marker panels which are rationally identified and proven
- Computer-assisted automatic result analysis system
Development Stage
